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Background: Cardiovascular (CV) mortality is higher in patients with rheumatoid arthritis (RA), in 
particular when anti–citrullinated protein antibodies (ACPA) are present. Recently, ACPA have also 
been described in a cohort of patients without RA, but with coronary artery disease (CAD). It is 
however unknown if ACPA can consistently be found in patients with CAD, and if ACPA are 
associated with mortality in these patients. The purpose of this study was to assess the relationship 
between ACPA and long-term outcomes including mortality in patients with ST-elevation myocardial 
infarction (STEMI) without RA. 
Methods: All patients with STEMI from the MISSION! Intervention Study were analyzed. Patients with 
RA were excluded. The association between ACPA (anti-CCP3) at baseline and 10 year mortality and 
re-infarction was investigated. 
Results: In total, 29 (11%) of 275 included patients were ACPA-positive, substantiating the previous 
description of ACPA in CAD patients. Increased cumulative cardiac mortality was observed in ACPA-
positive patients in comparison with ACPA-negative patients. Moreover, after correction for other 
associated factors, ACPA-positivity was associated with long-term mortality (HR 3.1 [CI 1.4-7.1] p-
Value = 0.01] and long-term combined endpoint of re-infarction and death (HR 2.4 [1.2-4.6] p-Value = 
0.01). 
Conclusion: In STEMI patients without RA, the presence of ACPA is independently associated with 
long-term mortality and the combined endpoint of re-infarction and death. ACPA in patients with and 




Inflammatory processes are known to play a key role in the development of coronary artery disease 
(CAD). Coronary atherosclerotic lesions are characterized by macrophage activation, fibrosis, 
production of matrix metalloproteinases (MMPs) and lipid deposition, factors which are associated 
with chronic low-grade inflammation. This might be the reason that CAD and vulnerable plaques are  
more prevalent in patients with chronic inflammatory diseases like rheumatoid arthritis (RA) (1). 
In RA approximately 60% of patients harbor antibodies directed against citrullinated proteins: so-
called anti-citrullinated protein antibodies (ACPA) (2). Citrulline is a post-translational modification of 
the amino acid arginine by the enzyme peptidylarginine deiminase (PAD), a process that frequently 
occurs in the context of inflammation (3). Interestingly, it has been shown that the cardiovascular risk 
is significantly higher in ACPA-positive versus ACPA-negative RA patients (4). Furthermore, it has 
been reported that citrullination of proteins also occurs in myocardium and atherosclerotic lesions (5, 
6). Although ACPA is thought to be very specific for RA (98%) (7), a recent study surprisingly found 
that 10% of the CAD patients without RA were ACPA-positive (8). Likewise, rheumatoid factor (RFhas 
also been reported to be associated with a high cardiovascular risk in patients without RA (ref 
Tomasson et al, Ann Rheum Dis 2010; 69: 1649-54). 
This raises the question whether 1) ACPA can consistently be found in non-RA patients with CAD and 
2) whether ACPA are associated with mortality in these patients. Therefore, we investigated if ACPA 
are associated with long-term mortality and re-infarction in patients without RA with established CAD.  
Methods 
 
Patients and outcomes 
The present study used data from patients with ST-segment elevation myocardial infarction (STEMI), 
who were included in the MISSION! Intervention Trial. The MISSION! Intervention Trial was 
conducted from February 2004 to October 2006 and investigated the use of either Bare Metal Stents 
(BMS) or Sirolimus Eluting Stents (SES) during primary percutaneous coronary intervention (PCI).(9) 
All patients were treated according to the institutional STEMI protocol, based on guidelines of the 
European Society of Cardiology, American College of Cardiology and the American Heart 
Association.(10, 11) At inclusion, data were collected regarding patient demographics, risk factors and 
clinical characteristics. SYNTAX score was used to assess CAD complexity by using baseline 
angiographic images obtained during the index procedure after reperfusion of the culprit segment 
(12). Calculations were performed by an experienced interventional cardiologist. Patients with prior 
myocardial infarction (n=11) or prior revascularization (n=7) were excluded. In addition, chart review 
was performed for all ACPA-positive patients to determine whether they had a previous rheumatic 
disease, or developed a rheumatic disorder during the long-term follow-up period . These patients 
(n=8) were also excluded for analysis. To investigate long-term outcome, 10 year all-cause mortality 
and the combined endpoint of 10 year all-cause mortality and re-infarction (with and without ST-
segment elevation) was assessed. Information on all-cause mortality was obtained from the Dutch 
Municipality Records registry. Cause of death was retrieved from general practitioners. Follow-up data 
on serious adverse events including myocardial infarction, new revascularisation and stroke was 
obtained by telephone interviews at 2, 5 and 10 years after admission. The study was approved by 
the institutional ethical committee. Written informed consent was obtained from all patients before 
enrolment in the study.  
 
Autoantibody testing 
Baseline serum samples drawn before primary PCI were used ACPA analysis. ACPA positivity was 
determined using a commercially available ELISA system for anti-CCP3 testing (Quanta Lite™ 
CCP3.1 IgG/IgA Cat# 704550, INOVA Diagnostics Inc., US). According to supplier’s manual, values 
above 20 aU/mL were considered positive. ACPA-levels in patients from the MISSION Intervention 
trial were compared with ACPA-levels derived from sera of 160 healthy controls aged between 20 and 
70 years from the Leiden area (13). 
 
Statistical analysis 
Normally distributed continuous variables were reported as mean and standard deviation, and 
compared with Student’s t-test. Skewed distributed continuous variables were reported as median 
and interquartile range, and compared with Mann-Whitney U test. Categorical variables were reported 
as number and percentage, and compared with Pearson’s chi-square test. Event-free survival was 
analyzed with Kaplan-Meier estimates and compared between groups with the log-rank test. Cox 
regression was performed to assess the association between the ACPA-positivity and primary and 
secondary outcome measures. Other variables used for the analysis included: sex, BMI, previous 
hypertension and/or smoking, out of hospital cardiac arrest, anterior infarction, infarct size, number of 
vessels diseased (>50%), complete revascularization, culprit vessel, proximal lesion, TIMI flow before 
intervention and drug-eluting stent during primary PCI. Variables were used in multivariable models in 
case the univariable p-value was <0.10. All statistical tests were performed with SPSS software 
(Version 22.0, SPSS IBM Corp., Armonk, New York). P-Values <0.05 assessed by two-sided tests 




A total of 275 STEMI patients from the MISSION! Intervention study had no history of RA or RA 
during the follow-up period and were included in the analysis. A positive ACPA test was found in 11% 
(29/275) of the included patients, which is significantly more than the 2% (3/160) of ACPA positive 
tests in a healthy control population (p-Value < 0.01) (Figure 1). ACPA-positive and ACPA-negative 
patients did not differ significantly with regard to demographics, risk factors, clinical and angiographic 
characteristics. However, there were some differences between ACPA-positive and ACPA-negative 
patients that reached no statistical significance: age, female sex, infarct size, multi-vessel CAD and C-
reactive protein (CRP) levels (Table 1). 
Median long-term follow-up was 9.4 years [IQR 8.7-9.9]. In ACPA-positive patients, cumulative 
mortality was significantly higher than in ACPA-negative patients (ACPA-positive patients 8/29 (28%) 
vs. ACPA-negative patients 27/246 (11%), (log-rank p-Value < 0.01) (Figure 2A). Cardiac cause of 
death was more prevalent in ACPA-positive patients (ACPA-positive patients 4/29 (14%) vs. ACPA-
negative patients 9/246 (4%), log-rank p-Value < 0.01), which was either heart failure or re-infarction. 
The combined long-term endpoint of re-infarction and/or death occurred more frequently in ACPA-
positive patients as well (ACPA-positive patients 11/29 (38%) vs. ACPA-negative patients 54/246 
(22%), log-rank p-Value = 0.03) (Figure 2B).  
To assess if advanced coronary atherosclerosis might be in the causal pathway of ACPA-positivity 
and re-infarction and/or death, SYNTAX score after reperfusion was included in the multivariable Cox 
regression analysis. Even then ACPA-positivity remained independently associated with long-term 
mortality (HR 3.1 [95% CI 1.4-7.2] p-Value < 0.01) and re-infarction and/or death (HR 2.4 [95% CI 1.2-
4.6] p-Value = 0.01) (Table 2). No significant correlation was found between ACPA levels and 







Key findings of this study are: 1) approximately 11% of non-RA patients with established CAD are 
ACPA-positive, corroborating previous results, and 2) ACPA-positivity is independently associated 
with long-term mortality and/or re-infarction in these patients.  
ACPA are widely recognized as the most disease-specific marker for RA. Moreover, ACPA are 
associated with a more severe disease course in RA with e.g. more joint destruction. The most potent 
risk factors for RA have been shown to be specifically associated with ACPA-positive disease: genetic 
features (HLA, the majority of predisposing SNPs) and smoking (14). This raises the question whether 
these factors are also associated with the presence of ACPA in RA-negative patients. In this study, 
current smoking status was not significantly different between ACPA-positive and -negative CAD 
patients. Further studies are therefore required to elucidate whether genetic predisposition is also 
associated with ACPA development in CAD patients without RA.  
Interestingly, we also found an association between ACPA levels and long-term clinical outcomes in 
patients with ACPA levels below the cutoff of 20 aU/mL (data not shown). This cut-off yields optimal 
sensitivity and specificity for diagnosing RA, but lower levels might well be meaningful in other 
settings. Our findings indicate that even low ACPA levels might play a role in the progression of CAD. 
The association between ACPA and with long-term outcome in patients with CAD without RA in our 
study, is in line with the current evidence of the prognostic role of ACPA in patients with RA for 
development of either cardiovascular (CV) disease and death (Hansson et al., 2011, 14, 15). The fact 
that we now find an association between ACPA and CAD in the absence of RA, raises interest in the 
role of these autoantibodies and anti-citrulline autoimmunity in the atherosclerotic disease process. 
One could envisage a contribution of these autoantibodies to atherosclerosis in the following manner: 
citrullinated proteins have been demonstrated in both atherosclerotic plaques and perivascular 
interstitium (5,6). If ACPA bind to these proteins, it appears likely that they would be able to exert their 
known effects of complement activation and the engagement of Fc-receptors on macrophages, 
leading to the production of inflammatory cytokines (7, 14). This could augment the inflammatory 
processes already taking place in the vessel walls in the context of atherosclerosis. Therefore the 
presence of ACPA, both in patients with and without RA, could accelerate plaque formation and 
rupture, and thereby lead to increased mortality (3).  
The exact citrullinated antigens in the vasculature remain to be identified. In clinical studies including 
patients with RA, high levels of ACPA targeting specifically citrullinated histone 2B were associated 
with subclinical atherosclerosis, whereas the association between ACPA targeting citrullinated 
fibrinogen and subclinical atherosclerosis could not be demonstrated (16, 17). 
Enhancement of the inflammatory process of atherosclerosis by ACPA would explain why the rate of 
ACPA-positivity is significantly higher in patients with STEMI compared to healthy controls, and why 
these patients have a higher risk of re-infarction and/or death. We determined if advanced coronary 
atherosclerosis (as measured by the SYNTAX score after reperfusion) was in the causal pathway of 
ACPA-positivity and re-infarction and/or death by adjusting the multivariable analyses for SYNTAX-
score. However, ACPA-positivity remained significantly associated with the clinical outcomes. There 
are several possible explanations for this finding; either SYNTAX-score may in this case not 
completely capture or reflect coronary atherosclerosis, or ACPA might exert their effect via a different 
pathway. 
The association between ACPA-positivity and progressive CAD warrants further study. If ACPA are 
indeed found to be pro-atherogenic, this may alter the common concept of the pathophysiology of 
CVD. As a consequence, immunosuppression could become a novel treatment option, as is already 
being investigated. (18) Additionally, if future research confirms our findings, ACPA could be a new 
biomarker for CVD and predict a worse long-term outcome. 
 
Limitations 
This study is the first to describe the association of long-term mortality and/or re-infarction and ACPA 
in patients without RA. Limitations of the current study are the observational study design, precluding 
conclusions about causality, and the use of 1 cohort with a limited sample size. Therefore, we were 
unable to test associations in subgroups, restricting the applicability of the findings to other patient 
groups. However, the results of our study confirm previous findings, indicating reproducibility. 
Strengths are the long duration of follow-up and stringent control for and exclusion of patients who 
developed RA. The treatment according to a strict protocol both in-hospital and during outpatient 




In conclusion, we found that the presence of ACPA was independently associated with long-term 
mortality and/or re-infarction in patients with myocardial infarction without RA. ACPA might therefore 
act as an independent pro-atherogenic factor in patients both with and without RA. Future research is 
required to provide more insight into the development of anti-citrulline autoimmunity in patients with 
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Figure 1. ACPA levels in the MISSION! Intervention cohort (n = 275) and a healthy control group (n = 
160). The horizontal line indicates the upper limit of the normal range of 20 aU/mL, considered 
CCP3.1 positive.  
Figure 2. A) Long-term cumulative mortality in ACPA-positive vs. ACPA-negative patients. B) Long-











    N = 246 N = 29  
  no. (%) no. (%) p-Value 
Age, mean (SD), y   58.4 (11.6) 62.7 (10.4) 0.06 
Woman   55 (22) 10 (34) 0.15 
Body mass index, mean (SD), kg/m2   26.5 (4.1) 27.0 (5.5) 0.59 
Treated hypertension†   70 (28) 6 (21) 0.38 
Diabetes   23 (9) 2 (7) 0.66 
Treated hyperlipidemia‡   44 (18) 4 (14) 0.58 
Current smoker   136 (55) 16 (55) 0.99 
Family history of CVD   108 (44) 14 (48) 0.67 
Out of hospital cardiac arrest   7 (3) 0 (0) 0.36 
Cardiogenic shock   5 (2) 0 (0) 0.45 
Anterior infarction   128 (55) 17 (63) 0.41 
Infarct size, median (IQR), g/m2   8.6 (4.4-15.4) 13.1 (4.7-18.7) 0.25 
Number of vessels diseased (>50%) 1 141 (58) 13 (45) 0.18 
  2 92 (38) 15 (52) 0.14 
  3 11 (5) 1 (3) 0.79 
Complete revascularization   244 (100) 29 (100) ~ 
Culprit vessel RCA 74 (30) 8 (28) 0.78 
  LAD 133 (54) 17 (59) 0.64 
  LCX 39 (16) 4 (14) 0.77 
Proximal lesion   126 (51) 12 (41) 0.32 
TIMI 0 flow before intervention   169 (69) 20 (71) 0.81 
Drug-eluting stent   124 (50) 11 (38) 0.20 
Reversible ischemia post-infarct 
myoview 
  96 (43) 11 (46) 0.78 
SYNTAX score after reperfusion   9.0 (7.0-13.0) 8.0 (4.3-14.5) 0.39 
 
Abbreviations: ACPA, anti-citrullinated protein antibodies; BMI, body mass index; CABG, coronary 
artery bypass graft surgery; CVD, cardiovascular disease; IQR, Interquartile Range; PCI, 
percutaneous coronary intervention; SD, standard deviation  
† Defined as systolic blood pressure ≥140 mm Hg and/or diastolic blood pressure ≥90 mm Hg and/or 
the use of antihypertensive medication.  
‡ Serum total cholesterol ≥6.0 mmol/L and/or serum TG ≥2.2 mmol/L or treatment with lipid lowering 
drugs. 
  
Table 2. Univariable and multivariable Cox regression analysis for 10-years all-cause mortality and 








    HR (95% CI) p-Value HR (95% CI) p-Value 
10-years All-Cause Mortality* 
     
Age, mean (SD), y   1.11 (1.07-1.16) 0.00 1.11 (1.07-1.16) 0.00 
Woman   0.74 (0.33-1.70) 0.48 - - 
Body mass index, mean (SD), kg/m2   0.97 (0.88-1.05) 0.43 - - 
Treated hypertension†   1.02 (0.49-2.12) 0.96 - - 
Diabetes   2.20 (0.92-5.30) 0.08 2.10 (0.85-5.22) 0.11 
Treated hyperlipidemia‡   1.04 (0.43-2.51) 0.92 - - 
Current smoker   0.66 (0.34-1.27) 0.21 - - 
Family history of CVD   0.52 (0.26-1.06) 0.07 0.64 (0.29-1.43) 0.28 
Out of hospital cardiac arrest   0.05 (0.00-519.47) 0.52 - - 
Cardiogenic shock   4.22 (1.01-17.66) 0.05 4.10 (0.95-17.69) 0.06 
Anterior infarction   0.83 (0.41-1.67) 0.60 - - 
Infarct size, median (IQR), g/m2   1.00 (0.96-1.03) 0.86 - - 
Number of vessels diseased (>50%)   1.50 (0.89-2.52) 0.13 - - 
Culprit vessel RCA ref 0.79 - - 
  LAD 1.25 (0.60-2.59) 0.55 - - 
  LCX 1.27 (0.51-3.21) 0.61 - - 
Proximal lesion   1.05 (0.54-2.01) 0.90 - - 
TIMI 0 flow before intervention   0.60 (0.31-1.16) 0.13 - - 
Drug-eluting stent   1.33 (0.69-2.56) 0.40 - - 
Reversible ischemia post-infarct 
myoview   0.54 (0.24-1.23) 0.14 - - 
SYNTAX score after reperfusion   0.99 (0.94-1.04) 0.66 - - 
ACPA>20 aU/mL   3.05 (1.39-6.73) 0.01 3.12 (1.36-7.16) 0.01 
10-years Re-infarction or Death*      
Age, mean (SD), y   1.02 (1.00-1.04) 0.07 1.02 (0.99-1.04) 0.18 
Woman   0.79 (0.44-1.42) 0.43 - - 
Body mass index, mean (SD), kg/m2   1.00 (0.95-1.06) 0.91 - - 
Treated hypertension†   0.89 (0.52-1.55) 0.69 - - 
Diabetes   2.09 (1.07-4.10) 0.03 2.00 (0.96-4.14) 0.06 
Treated hyperlipidemia‡   1.92 (1.11-3.32) 0.02 1.90 (1.04-3.49) 0.04 
Current smoker   1.07 (0.66-1.72) 0.80 - - 
Family history of CVD   0.62 (0.38-1.02) 0.06 0.52 (0.30-0.91) 0.02 
Out of hospital cardiac arrest   0.05 (0.00-32.00) 0.36 - - 
Cardiogenic shock   1.73 (0.42-7.15) 0.45 - - 
Anterior infarction   0.82 (0.50-1.35) 0.43 - - 
Infarct size, median (IQR), g/m2   1.00 (0.97-1.03) 0.95 - - 
Number of vessels diseased (>50%)   1.31 (0.88-1.94) 0.18 - - 
Culprit vessel RCA ref 0.71 - - 
  LAD 1.23 (0.72-2.10) 0.45 - - 
  LCX 1.22 (0.62-2.40) 0.57 - - 
Proximal lesion   1.36 (0.84-2.20) 0.21 - - 
TIMI 0 flow before intervention   0.83 (0.50-1.39) 0.48 - - 
Drug-eluting stent   1.13 (0.70-1.82) 0.62 - - 
Reversible ischemia post-infarct 
myoview   1.04 (0.61-1.77) 0.88 - - 
SYNTAX score after reperfusion  2.10 (0.96-4.61) 0.07 2.32 (1.04-5.15) 0.04 
ACPA>20 aU/mL   2.07 (1.08-3.95) 0.03 2.35 (1.21-4.56) 0.01 
 
Abbreviations: ACPA, anti-citrullinated protein antibodies; BMI, body mass index; CABG, coronary 
artery bypass graft surgery; CVD, cardiovascular disease; PCI, percutaneous coronary intervention 
*Causes of death were: 
in ACPA-negative patients: COPD (2), CVA (1), heart failure (3), infection (2), malignancy (10), 
myocardial infarction (4), sudden cardiac death (2), unknown (3);  
in ACPA-positive patients: Heart failure (1), liver failure (1), malignancy (2), myocardial infarction (2), 
sudden cardiac death (1), unknown (1). 
† Defined as systolic blood pressure ≥140 mm Hg and/or diastolic blood pressure ≥90 mm Hg and/or 
the use of antihypertensive medication.  
‡ Serum total cholesterol ≥6.0 mmol/L and/or serum TG ≥2.2 mmol/L or treatment with lipid lowering 
drugs. 
 
